Adherence to glaucoma medication higher in the mornings


Patient adherence to glaucoma medication could increase with morning application of glaucoma medication.

Patient adherence to glaucoma medication could increase with morning application of glaucoma medication, reveals a paper in the Journal of Glaucoma.

The prospective, randomized crossover treatment trial, conducted by Dr Bryce A. Ford et al., Department of Surgery, Division of Ophthalmology, University of Calgary, Alberta, Canada, involved 30 patients with glaucoma or ocular hypertension.

All patients initially received travoprost eye drops and were randomized to either morning or evening administration for one month. They were then crossed over to the opposite dosing schedule for the second month.

The main outcome measures were adherence between morning versus evening dosing and between first and second month dosing. Patients completed a post-study questionnaire on the convenience of the two dosing schedules.

Patient adherence overall was 89.3% and there was no significant difference between adherence for morning and evening dosing. However, patients claimed to prefer morning administration to evening administration and males were more likely to demonstrate a greater adherence for morning administration.

Adherence decreased from the first month to the second month and IOP response was not significantly affected by morning or evening administration.

The abstract can be read here.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.